News

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

  • Caisse régionale de Crédit Agricole Mutuel d'Ille-et-Vilaine, société coopérative à capital variable, agréée en tant qu'établissement de crédit, société de courtage d'assurance immatriculée auprès de l'ORIAS sous le n°07 023 057.Siège social : 4, rue Louis Braille - 35136 Saint-Jacques de la Lande.N° SIREN : 775.590.847 Communiqué de mise à disposition du rapport financier annuel 2024 de la Caisse régionale du Crédit Agricole d'Ille-et-Vilaine Le Crédit Agricole d'Ille-et-Vilaine informe le public que son rapport financier annuel a été déposé auprès de l'AMF et est disponible sur le site internet de la Société. Il peut être consulté sur le site Internet du Crédit Agricole d'Ille-et-Vilaine : www.ca-illeetvilaine.fr, dans l'espace «  Informations règlementaires et financières  » / Rapports annuels et semestriels.
    03/27/2025

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

  • Paris, le 21 mars 2025 Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE Le Groupe BPCE informe que le document d'enregistrement universel 2024 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) le 21 mars 2025 sous le n° D.25-0132. Ce document est tenu gratuitement à la disposition du public dans les conditions prévues par la réglementation en vigueur.
    03/21/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Rapport Therapeutics, Inc. Common Stock (RAPP) can sell. Click on Rating Page for detail.

The price of Rapport Therapeutics, Inc. Common Stock (RAPP) is 9.02 and it was updated on 2025-04-04 13:00:21.

Currently Rapport Therapeutics, Inc. Common Stock (RAPP) is in overvalued.

News
    
News

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

  • Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy
    Fri, Mar. 21, 2025

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

  • Vous trouverez en attaché les informations préparatoires aux Assemblées Générales Ordinaires et Extraordinaires 2025 qui auront lieu en date du 28 mars 2025. Une version PDF est disponible sur le portail de la Caisse région l'adresse suivante https://www.credit-agricole.fr/ca-tourainepoitou/particulier/informations/informations-reglementees.html#AG Attachment Informations préparatoires aux Assemblées Générales Ordinaire et Extraordinaire 2025
    Thu, Mar. 13, 2025

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

  • Vous trouverez en attaché les informations préparatoires aux Assemblées Générales Ordinaires et Extraordinaires 2025 qui auront lieu en date du 28 mars 2025. Une version PDF est disponible sur le portail de la Caisse région l'adresse suivante https://www.credit-agricole.fr/ca-tourainepoitou/particulier/informations/informations-reglementees.html#AG Attachment Avis de convocation aux AGE et AGO du 28 mars 2025
    Thu, Mar. 13, 2025

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

  • Vous trouverez en attaché les informations préparatoires aux Assemblées Générales Ordinaires et Extraordinaires 2025 qui auront lieu en date du 28 mars 2025.
    Thu, Mar. 13, 2025

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

  • Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025 Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter and full year ended December 31, 2024, and provided a business update.
    Tue, Mar. 11, 2025
SEC Filings
SEC Filings

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 03/17/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 03/13/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - S-8

  • SEC Filings
  • 03/11/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 03/11/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 10-K - Current report

  • SEC Filings
  • 03/11/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 03/05/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 3

  • SEC Filings
  • 03/05/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 03/03/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - SCHEDULE 13G

  • SEC Filings
  • 02/13/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 02/04/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 01/10/2025

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G/A

  • SEC Filings
  • 11/14/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 11/14/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 11/13/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G/A

  • SEC Filings
  • 11/12/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 11/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 11/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 3

  • SEC Filings
  • 11/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 10/18/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 08/08/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/08/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SEC STAFF LETTER

  • SEC Filings
  • 07/26/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 07/10/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 07/03/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G/A

  • SEC Filings
  • 06/24/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 06/21/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13G

  • SEC Filings
  • 06/20/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SC 13D

  • SEC Filings
  • 06/14/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-K - Current report

  • SEC Filings
  • 06/10/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 4

  • SEC Filings
  • 06/10/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - EFFECT

  • SEC Filings
  • 06/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - S-8

  • SEC Filings
  • 06/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 424B4

  • SEC Filings
  • 06/07/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - CERT

  • SEC Filings
  • 06/06/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 3

  • SEC Filings
  • 06/06/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - CORRESP

  • SEC Filings
  • 06/04/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - 8-A12B

  • SEC Filings
  • 06/04/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - S-1/A

  • SEC Filings
  • 06/03/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - CORRESP

  • SEC Filings
  • 06/03/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - CORRESP

  • SEC Filings
  • 05/29/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - UPLOAD

  • SEC Filings
  • 05/24/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - S-1

  • SEC Filings
  • 05/17/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - CORRESP

  • SEC Filings
  • 05/17/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - UPLOAD

  • SEC Filings
  • 05/13/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - SEC STAFF LETTER

  • SEC Filings
  • 05/03/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - DRSLTR

  • SEC Filings
  • 04/29/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - DRS/A

  • SEC Filings
  • 04/29/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - UPLOAD

  • SEC Filings
  • 04/24/2024

Rapport Therapeutics, Inc. Common Stock (RAPP) - DRS

  • SEC Filings
  • 03/27/2024
Press Releases
StockPrice Release

CrÉdit agricole ille-et-vilaine : communiquÉ de mise À disposition du rapport financier 2024

  • 03/27/2025

Bpce: mise À disposition du document d'enregistrement universel 2024 et du rapport financier annuel du groupe bpce

  • 03/21/2025

Rapport therapeutics to present data at the 2025 american academy of neurology annual meeting

  • 03/21/2025

Correction: mise À disposition des ÉlÉments prÉparatoires À l'ag du 28/03/2025 - rapport financier annuel 2024

  • 03/13/2025

Correction: mise À disposition des ÉlÉments prÉparatoires À l'ag du 28/03/2025 - rapport financier annuel 2024

  • 03/13/2025

Mise À disposition des ÉlÉments prÉparatoires À l'ag du 28/03/2025 - rapport financier annuel 2024

  • 03/13/2025

Rapport therapeutics reports fourth quarter and full year 2024 financial results and provides business update

  • 03/11/2025

Rapport therapeutics announces appointment of dr. jeffrey sevigny as chief medical officer to drive clinical strategy and precision medicine development

  • 03/03/2025

Rapport therapeutics to participate in upcoming investor conferences

  • 02/24/2025

Correction -- rapport therapeutics announces new phase 1 data, further supporting rap-219's transformative potential for cns disorders

  • 01/09/2025

Rapport therapeutics announces new phase 1 data, further supporting rap-219's transformative potential for cns disorders

  • 01/09/2025

Rapport therapeutics presents data demonstrating consistent association between decreases in rns measured long episodes and meaningful reductions in clinical seizures

  • 12/06/2024

Rapport therapeutics to present data at american epilepsy society annual meeting

  • 11/14/2024

Rapport therapeutics to present at stifel healthcare conference and jefferies london healthcare conference in november

  • 11/04/2024

Rapport semestriel pilier 3 - 30 juin 2024

  • 09/17/2024

Rapport therapeutics to present at upcoming epilepsy medical conferences

  • 09/05/2024

Rapport therapeutics to present at 22nd annual morgan stanley global healthcare conference and td cowen's 4th annual novel mechanisms in neuropsychiatry summit

  • 08/29/2024

Rapport therapeutics to present data for tarpΓ8 ampar negative modulator at iasp 2024 world congress on pain

  • 07/29/2024

Rapport therapeutics announces closing of $174 million initial public offering, including full exercise of underwriters' option to purchase additional shares and concurrent private placement

  • 06/12/2024

Rapport therapeutics announces pricing of initial public offering

  • 06/06/2024
More Headlines
News

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

  • BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases.
  • 03/03/2025

Rapport Therapeutics to Participate in Upcoming Investor Conferences

  • BOSTON and SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences in March 2025. TD Cowen 45 th Annual Health Care Conference (Boston) – fireside chat on Tuesday, March 4, 2025, at 3:10-3:40pm EST.
  • 02/24/2025

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

  • Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
  • 01/09/2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

  • Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
  • 01/09/2025

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

  • A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode frequency is the primary endpoint for Rapport's ongoing Phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 Data from additional studies, including preclinical seizure data and Phase 1 pharmacokinetic and safety trial results, support the potential of RAP-219 as a transformational treatment for patients with focal epilepsy BOSTON and LOS ANGELES, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, presents novel findings on the association between a seizure biomarker used in the Company's proof-of-concept trial for RAP-219 and clinical seizures. The analysis demonstrated a linear relationship between changes in long episode (LE) frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction.
  • 12/06/2024

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

  • Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data
  • 11/14/2024

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

  • BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows:
  • 11/04/2024

Rapport semestriel Pilier 3 - 30 juin 2024

  • Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 - 30 juin 2024
  • 09/17/2024

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

  • BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024.
  • 09/05/2024

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

  • BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:
  • 08/29/2024

The 3 Best Healthcare Stocks to Buy in August 2024

  • The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027.
  • 08/12/2024

3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns

  • Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.
  • 08/06/2024

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

  • Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models
  • 07/29/2024

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

  • BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport's shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.
  • 06/12/2024

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

  • Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
  • 06/07/2024

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

  • Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
  • 06/06/2024

Rapport Therapeutics Announces Pricing of Initial Public Offering

  • BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the pricing of its initial public offering of 8,000,000 shares of its common stock at a public offering price of $17.00 per share. Rapport's shares are expected to begin trading on the Nasdaq Global Market on June 7, 2024 under the ticker symbol “RAPP.” The offering is expected to close on June 10, 2024, subject to the satisfaction of customary closing conditions. In addition, Rapport has granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Rapport.
  • 06/06/2024

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

  • Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their shares amid a rebound in the capital markets.
  • 06/03/2024

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

  • Rapport Therapeutics, Inc. has filed for a $100 million IPO to develop treatment candidates for central nervous system and related disorders. The company's lead candidate, RAP-219, is being developed to treat Focal Epilepsy, peripheral nerve pain, and bipolar disorder. Rapport Therapeutics is backed by top-tier life science venture capital firms and has connections to Johnson & Johnson, so the IPO is one to watch.
  • 05/22/2024
Unlock
RAPP Ratings Summary
RAPP Quant Ranking